A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001